亚虹医药：APL-1401Ⅰb期临床试验数据在ECC发布

Core Viewpoint - The company announced that its clinical trial results for APL-1401, aimed at treating moderate to severe active ulcerative colitis, have been selected for presentation at the 19th European Colorectal Congress (ECC) in the form of a poster [1] Group 1 - The clinical trial for APL-1401 is in the Phase Ib stage [1] - The results of the trial have been recognized and will be shared at a significant industry event, indicating potential interest and validation from the medical community [1]